Human Interleukin-2 (hIL-2)

Source: Recombinant human IL-2 (hIL-2) Ala21-Thr153 (Accession NM_000586) was produced in E. coli at Cell Signaling Technology.

Molecular Characterization: Recombinant hIL-2 does not have a Met on the amino terminus and has a calculated MW of 15,418. DTT-reduced and non-reduced protein migrate as 14 kDa polypeptides with non-reduced protein having slightly greater mobility due to an intramolecular cystine. The expected amino-terminal APTSS of recombinant hIL-2 was verified by amino acid sequencing.

Endotoxin: Less than 0.01 ng endotoxin/1 µg hIL-2.

Purity: >98% as determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-2. All lots are greater than 98% pure.

Bioactivity: The bioactivity of recombinant hIL-2 was determined in a CTLL-2 cell proliferation assay. The ED50 of hIL-2 was assessed. After 48 hours treatment with hIL-2, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Western blot analysis of extracts from CTLL-2 cells, untreated or treated with hIL-2 for 20 minutes, using Phospho-S6 Ribosomal Protein (Ser235/236) Rabbit mAb #4856 (upper) or S6 Ribosomal Protein (SG10) Rabbit mAb #2217 (lower).

The proliferation of CTLL-2 cells treated with increasing concentrations of hIL-2 was assessed. After 48 hours treatment with hIL-2, cells were incubated with a tetrazolium salt and the OD450 - OD450 was determined.

Background References: